The program aims to help people in the U.S. access the Eversense E3 continuous glucose monitor (CGM) more affordably. It offers major savings for eligible individuals looking to experience the benefits of the long-term, implantable CGM.
Eversense E3, a 180-day CGM, requires two sensor insertion and removal procedures per year. It offers a mean absolute relative difference (MARD — an accuracy metric for CGMs) of 8.5%. The system features predictive on-body alerts to never miss a critical event. Senseonics develops the sensor and Ascensia serves as the global exclusive distributor for Eversense E3.
Senseonics also has the regulatory wheels in motion for Eversense E3 with a 365-day wear time. The company expects an “imminent” submission to the FDA.
Get the full story at our sister site, Drug Delivery Business News.